BioSpace News Archive

New Research Suggests That Healthcare System Must Make Critical Changes in Current Treatment Models to Help Treat Lung Cancer Patients with COVID-19

Citigroup Global Markets Inc. (“Citigroup”), in its capacity as Joint Global Coordinator, notifies that stabilization measures have been undertaken in Calliditas Therapeutics AB’s (“Calliditas” or the “Company”) American Depositary Shares (“ADSs”), traded on The Nasdaq Global Select Market.

The Department of Health and Human Services finalized a rule that revises 2016 provisions of the Obamacare section 1557 rule that had redefined discrimination “on the basis of sex” to include “gender identity” and “pregnancy termination.”

Transparency Market Research has published a new report titled, “Cardiac Ablation Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Transparency Market Research has published a new report titled, “Blood Group Typing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018 to 2026.” According to the report, the global blood group typing market was valued at US$ 1,500.0 Mn in 2017 and is projected to reach US$ 3,556.0 Mn by 2026, expanding at a high CAGR of 10.3% from 2018 to 2026.

A cell bank refers to a facility that helps in the storage of cells of certain genome for future use in medicinal needs or in some product.

Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with Pyruvate Kinase Deficiency or Expected in the Context of Sickle Cell Disease

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company pioneering targeted C3 therapies, presented detailed results from the Phase 3 PEGASUS study, which in January showed superiority for pegcetacoplan over eculizumab in improving hemoglobin levels in adults with paroxysmal nocturnal hemoglobinuria.

PNH is a rare but severe and usually life-long blood disease in which the blood cells are fragile and easily destroyed by a part of the patient’s own immune system, called complement.

CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in transfusion-dependent beta thalassemia and severe sickle cell disease, and highlighted recent progress in the CTX001 development program.